Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Turning Point Therapeutics, Inc. of its common stock for up to an aggregate amount of $250 million.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Daniel Reichert and Dana Lueck-Mammen. Counsel Ethan R. Goldman and associate M. Jared Sanders provided tax advice. Counsel Daniel F. Forester and associate Jennifer Leather provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.